Demographic, clinical characteristics, treatment outcome and determinant factors of patients with multiple myeloma at TASH from January 2015 to December 2019
| dc.contributor.advisor | Dr.Gebremedhin, Amha (Consultant Internist, Hematologist,Associate Professor of Medicine) | |
| dc.contributor.author | Haile, Ephrem | |
| dc.date.accessioned | 2021-02-03T06:06:46Z | |
| dc.date.accessioned | 2023-11-05T09:37:02Z | |
| dc.date.available | 2021-02-03T06:06:46Z | |
| dc.date.available | 2023-11-05T09:37:02Z | |
| dc.date.issued | 2020-12 | |
| dc.description.abstract | Background of the study Patients with multiple myeloma are being seen in increasing frequency in different hospitals of the country. However, local data regarding the demographic, clinical characteristics, treatment outcome, and risk stratification of patients is lacking. This study was designed to fill this existing gap in our setup. This will aid in the revision of treatment regimens based on a local data on the efficacy of treatment regimens and risk stratification of patients with a newly diagnosed Myeloma Patients and Methods A single centered Hospital-based retrospective Cohort study was conducted from January 2015 to December 2019. A total of 80 patients with newly diagnosed MM who received non Proteasome inhibitor based therapy at TASH, Addis Ababa, Ethiopia were analyzed in the study. Results In this cohort 63.8% of the patients were males (M:F ratio 1.76:1) and the median age at diagnosis was 52 years. The commonest complications identified were Anemia (56.3%) and pathologic fracture (55%). The commonest comorbid conditions were; systemic hypertension (24%), CKD (6.3%), and Diabetes (5%). The median PFS and OS of patients were found to be 17.5 and 20 months respectively. This study also identified factors like advanced DS stage, presence of Plasmacytoma, renal dysfunction, elevated serum LDH, high level of serum protein, and Monoclonal M protein to be significant contributors in negatively affecting OS and PFS of patients. Conclusion In our setup, Myeloma is more common in the male population group and our patients are younger than the western population. Myeloma treatment regimens like CP and CPT are found to perform less in our patients than in patients elsewhere. This is likely due to the advanced stage at presentation. In resource-limited areas, different clinical and laboratory parameters can still serve as of patient survival. | en_US |
| dc.identifier.uri | http://etd.aau.edu.et/handle/123456789/24934 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Addis Abeba University | en_US |
| dc.subject | Multiple myeloma, clinical characteristics, PFS, OS, prognostic markers | en_US |
| dc.title | Demographic, clinical characteristics, treatment outcome and determinant factors of patients with multiple myeloma at TASH from January 2015 to December 2019 | en_US |
| dc.type | Thesis | en_US |